12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ND0612: Phase I/IIa started

NeuroDerm began a double-blind, placebo-controlled, crossover, Israeli Phase IIa trial to evaluate a single dose of subcutaneous ND0612 in about 8 patients. The trial includes a 1-week...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >